$1.95
+0.0100 ( +0.52% ) 9.0K
Clinical Trial Pipeline Stages
| Drug Name | Stage |
|---|---|
| INKmune™DetailsCastration-resistant prostate cancer, Cancer, Prostate cancer | Phase 2 |
| XPro1595 (XPro™)DetailsAlzheimer's disease | Phase 2 |
| INB03 + trastuzumab-deruxtecanDetailsCancer, Pancreatic cancer, Gastric cancer, HER2-expressing cancers, Breast cancer, Triple-negative breast cancer | Phase 2 |
| XPro1595 (XPro™) (pegipanermin fr)DetailsMental health, Major depressive disorder, Treatment Resistant Depression | Phase 2 |
| INKmune™DetailsCancer, Acute myeloid leukemia, Myelodysplastic syndrome | Phase 1 |
| LIVNateDetailsLiver disease, NASH-induced significant or severe fibrosis | Failed |
| Quellor™DetailsCOVID-19 | Failed |
| INKmune™DetailsCancer, Myelodysplastic syndrome, Acute myeloid leukemia | Failed |
| INKmune™DetailsCancer, Prostate cancer, Castration-resistant prostate cancer | Phase 2 |
| XPro1595 (XPro™) (pegipanermin fr)DetailsMajor depressive disorder, Mental health, Treatment Resistant Depression | Phase 2 |
Market Data
| Open | $1.95 |
| Previous Close | $1.94 |
| Volume | 9.0K |
| Market Cap | $51.58M |
| Day Range | $1.90 - $1.97 |
| 52 Week Range | $1.09 - $3.24 |
| Shares Outstanding | 26.59M |
| Change % | +0.52% |
| Net Change | ▲ 0.0100 |
| Insider Ownership | -0.07% |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| IPO Year | 2019 |
| Country | United States |
Insider Ownership Transactions
Total Amount Purchased: -555,394.00
| Date | Type | Amount Purchased | Purchaser |
|---|---|---|---|
| 2024-05-16 | Sale | -12500.00 | Ganjei James Kelly |
| 2024-05-16 | Sale | -12500.00 | Baracchini Edgardo Jr |
| 2024-05-16 | Sale | -12500.00 | ALLEN MARCIA |
| 2024-04-23 | Sale | -18028.00 | Tesi Raymond Joseph |
| 2024-04-23 | Sale | -18028.00 | Moss David J |
| 2024-04-23 | Sale | -14423.00 | Lowdell Mark William |
| 2024-04-23 | Sale | -29603.00 | Juda Scott |
| 2023-11-13 | Buy | 7000.00 | Juda Scott |
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 45 | Nov 10, 2025 |
| 8-k | 8K-related | 14 | Oct 30, 2025 |
| 10-q | Quarterly Reports | 71 | Oct 30, 2025 |
| 8-k | 8K-related | 14 | Oct 28, 2025 |
| 8-k | 8K-related | 14 | Oct 14, 2025 |
| def | Proxies and info statements | 4 | Oct 14, 2025 |
| pre | Proxies and info statements | 4 | Oct 03, 2025 |
| 8-k | 8K-related | 14 | Sep 30, 2025 |
| 3 | Insider transactions | 1 | Aug 18, 2025 |
| 8-k | 8K-related | 17 | Aug 07, 2025 |
Latest News
Hello, I'm RedChat, your AI assistant for INMB